---
layout: post
title: New Drug Approvals 2011 - Pt. XIX Belatacept (NulojixTM)
date: '2011-06-27T05:54:00.004+01:00'
author: Patricia
tags:
- 2011 New Drugs
modified_time: '2011-07-05T07:23:53.458+01:00'
thumbnail: http://1.bp.blogspot.com/-r4jMOlhcll8/ThKt797xHjI/AAAAAAAABOQ/wdE08XkutO8/s72-c/ht_110616_nulojix_300x225.png
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-3419955782789300347
blogger_orig_url: http://chembl.blogspot.com/2011/06/new-drug-approvals-2011-pt-xix.html
---

<div style="text-align: center;"></div><div style="text-align: center;"><div class="separator" style="clear: both; text-align: center;"><a href="http://1.bp.blogspot.com/-r4jMOlhcll8/ThKt797xHjI/AAAAAAAABOQ/wdE08XkutO8/s1600/ht_110616_nulojix_300x225.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://1.bp.blogspot.com/-r4jMOlhcll8/ThKt797xHjI/AAAAAAAABOQ/wdE08XkutO8/s1600/ht_110616_nulojix_300x225.png" /></a></div><div style="font: 12.0px Helvetica; margin: 0.0px 0.0px 0.0px 0.0px;"><br />
</div><div style="font: 12.0px Helvetica; margin: 0.0px 0.0px 0.0px 0.0px;"></div></div><div><div class="separator" style="clear: both; text-align: center;"><a href="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,1,0,1" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="https://www.ebi.ac.uk/chembltools/autoiconlarge/5,0,0,0,1,0,1,0,1" width="400" /></a></div><div class="separator" style="clear: both; text-align: center;"><br />
</div><div class="separator" style="clear: both; text-align: center;"></div><div style="text-align: center;"><div style="text-align: center;"><b>ATC code:</b> <a href="http://www.whocc.no/atc_ddd_index/?code=L04AA28" title="ATC code L04AA28">L04AA28</a>  </div></div></div><div style="text-align: left;"><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">On June 15th 2011, the FDA has approved Belatacept (trade name: <a href="http://www.trademarkia.com/trademarks-search.aspx?tn=nulojix">Nulojix</a>; Research Code: BMS-224818), a selective <a href="http://en.wikipedia.org/wiki/T_cell">T-cell (lymphocyte)</a> <a href="http://en.wikipedia.org/wiki/Costimulation">costimulation</a> blocker indicated for phophylaxis of <a href="http://en.wikipedia.org/wiki/Transplant_rejection">organ rejection</a> in adult patients receiving a kidney transplant. Belatacept is approved for use in combination with other <a href="http://en.wikipedia.org/wiki/Immunosuppressant">immunosuppressants</a>, specifically basiliximab, mycophenolate mofetil and corticosteroids.</span></span><br />
<br />
Belatacept is a potent <a href="http://en.wikipedia.org/wiki/Receptor_antagonist">antagonist</a> that inhibits T-lymphocyte activation by binding to the <a href="http://en.wikipedia.org/wiki/B7_(protein)">B7-ligands</a>, namely <a href="http://en.wikipedia.org/wiki/CD80">CD80</a> (Uniprot: <a href="http://www.uniprot.org/uniprot/P33681">P33681</a>; Pfam: <a href="http://pfam.sanger.ac.uk/family?acc=PF08205">PF08205</a>, <a href="http://pfam.sanger.ac.uk/family?acc=PF07686">PF07686</a>) and <a href="http://en.wikipedia.org/wiki/CD86">CD86</a> (Uniprot: <a href="http://www.uniprot.org/uniprot/P42081">P42081</a>; Pfam: <a href="http://pfam.sanger.ac.uk/family?acc=PF07686">PF07686</a>), present on antigen-presenting cells, and thereby blocking interaction with <a href="http://en.wikipedia.org/wiki/CD28">CD28</a> (Uniprot: <a href="http://www.uniprot.org/uniprot/P10747">P10747</a>; Pfam: <a href="http://pfam.sanger.ac.uk/family?acc=PF07686">PF07686</a>), the receptor of these two ligands. This interaction provides a costimulary signal necessary for full activation of T-lymphocytes. Activated T-cells are the predominant mediators of immunologic rejection. <i>In vitro</i>, Belatacept inhibits T-cell proliferation and the <a href="http://en.wikipedia.org/wiki/Cytokines">cytokines</a> <a href="http://en.wikipedia.org/wiki/Interleukin-2">interleukin-2</a>, <a href="http://en.wikipedia.org/wiki/IFN-%CE%B3">interferon-γ</a>, <a href="http://en.wikipedia.org/wiki/Interleukin_4">interleukin-4</a> and <a href="http://en.wikipedia.org/wiki/TNF-alpha">TNF-α</a>.<br />
<br />
</div><div style="text-align: left;"><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"> </span></span></div><div style="text-align: left;"><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">There are some protein structures known for the B7-ligands, CD80 and CD86. Here are two typical entries for CD80 (<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1i8l/summary">PDBe:1i8l</a>) and CD86 (<a href="http://www.ebi.ac.uk/pdbe-srv/view/entry/1i85/summary">PDBe:1i85</a>) in complex with CTLA-4.</span></span></div><div style="text-align: left;"><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"> </span></span></div><div style="text-align: left;"><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5621744151037648306" src="http://2.bp.blogspot.com/-5TfcdYXYrM8/TgRyhSS6nbI/AAAAAAAAAmc/G6AQNilHKVc/s400/CD80_PDBe1i8l.png" style="cursor: hand; cursor: pointer; display: block; height: 300px; margin: 0px auto 10px; text-align: center; width: 400px;" /></span></span></div><div style="text-align: left;"><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><img alt="" border="0" id="BLOGGER_PHOTO_ID_5621741911148064562" src="http://1.bp.blogspot.com/-g9cwtTyYGOU/TgRwe6Dn7zI/AAAAAAAAAmU/Mvc-eyC49zs/s400/CD86_PDBe1i85.png" style="cursor: pointer; display: block; height: 300px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 0px; text-align: left; width: 400px;" />Belatacept is derived from Abatacept (trade name: Orencia; approved in 2005 for the treatment of <a href="http://en.wikipedia.org/wiki/Rheumatoid_arthritis">rheumatoid arthritis</a>, ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201823">CHEMBL1201823</a>), a soluble fusion protein that consists of the extracellular domain of the human <a href="http://en.wikipedia.org/wiki/CTLA-4">cytotoxic T-lymphocyte antigen-4 (CTLA-4</a>; Uniprot: <a href="http://www.uniprot.org/uniprot/P16410">P16410</a>; Pfam: <a href="http://pfam.sanger.ac.uk/family?acc=PF07686">PF07686</a>), linked to a modified Fc (hinge-CH2-CH3 domains) portion of human <a href="http://en.wikipedia.org/wiki/IgG1">immunoglobulin G1</a> (CTLA4-Ig). CTLA-4 is similar to the T-cell costimulatory protein CD28, and both molecules bind to CD80 and CD86 on antigen-presenting cells. However, CTLA-4 transmits an inhibitory signal to T-cells, whereas CD28 transmits a stimulatory signal.  Although Abatacept <a href="http://www.medscape.com/viewarticle/740269_3">binds</a> to the B-7 ligands with higher affinity when compared with CD28, it has never reached the market as an organ transplantation therapy due to the fact that it does not completely and equally block of the costimulation pathway (the difference in antagonistic effect to CD80 compared with CD86 is a 100-fold decrease in affinity to the CD86). Given this, Belatacept was <a href="http://www.ncbi.nlm.nih.gov/pubmed/15707398">developed</a> by altering two amino acids in the B-7 ligand-binding portion of the Abatacept molecule (a leucine and an alanine were replaced by a glutamic acid and a tyrosine, respectively). These modifications have resulted in a 4-fold increase in binding affinity to the CD86 and a 2-fold increase in CD80 binding affinity in comparison to Abatacept. Also, it has been shown that, <i>in vitro</i>, this increase in binding affinity to the B-7 ligands resulted in a 10-fold increase in inhibiting T-cell activation when compared with Abatacept.&nbsp;</span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span></span><br />
<pre>&gt;Belatacept
MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQ
GLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDT
LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA
PIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKL
TVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
</pre><pre></pre><span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Other immunosuppressive therapies to treat transplant rejection are available on the market and these include <a href="http://en.wikipedia.org/wiki/Calcineurin">calcineurin</a> inhibitors, such as Tacrolimus (ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1237096">CHEMBL1237096</a>), <a href="http://en.wikipedia.org/wiki/MTOR">mTOR</a> inhibitors, such as Everolimus (ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201755">CHEMBL1201755</a>), anti-proliferatives, such as Mycophenolic acid (ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL866">CHEMBL866</a>), <a href="http://en.wikipedia.org/wiki/Corticosteroids">corticosteroids</a>, such as Hydrocortisone (ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL389621">CHEMBL389621</a>) and antibodies, such as Basiliximab (ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201439">CHEMBL1201439</a>) and Rituximab (ChEMBLID: <a href="https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL1201576">CHEMBL1201576</a>).</span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">Belatacept recommended dosage is a 10 mg/kg intravenous infusion on days 1 (day of transplantation) and 5, end of weeks 2, 4, 8, and 12 after transplantation in the initial phase, followed by a maintenance phase of 5 mg/kg at the end of week 16 after transplantation and every 4 weeks thereafter.  The molecular weight of Belatacept is approximately 90 kDa. After a 10 mg/kg intravenous infusion at week 12, Belatacept has a volume of distribution (Vd) of 0.11 L/kg, a systemic clearance (CL) of 0.49 mL/h/kg and a terminal half-life (t1/2) is 9.8 days.  The full prescribing information can be found <a href="http://packageinserts.bms.com/pi/pi_nulojix.pdf">here</a>.&nbsp;</span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;"><br />
</span></span><br />
<span class="reflink plainlinks nourlexpansion"><span class="Apple-style-span" style="font-family: inherit;">The license holder is <a href="http://www.bms.com/">Bristol-Myers Squibb Company</a> and the product website is <a href="http://www.nulojix.com/">www.nulojix.com</a>.</span></span> </div>